Search results
Results From The WOW.Com Content Network
Tamsulosin, sold under the brand name Flomax among others, is a medication used to treat symptomatic benign prostatic hyperplasia (BPH) and chronic prostatitis and to help with the passage of kidney stones. [6] [7] [8] The evidence for benefit with a kidney stone is better when the stone is larger. [8] Tamsulosin is taken by mouth. [6]
It is a combination of two previously existing medications: dutasteride, brand name Avodart, and tamsulosin, brand name Flomax. It contains 0.5 mg of dutasteride and 0.4 mg of tamsulosin hydrochloride .
Ovarian cancer most often occurs after menopause with 50% of these cancers developing after age 63, the American Cancer Society notes. Symptoms of borderline ovarian tumors are the same as “any ...
1900 – Swedish Dr. Stenbeck cures a skin cancer with small doses of radiation [4]; 1920s – Dr. William B. Coley's immunotherapy treatment, regressed tumors in hundreds of cases, the success of Coley's Toxins attracted heavy resistance from his rival and supervisor, Dr. James Ewing, who was an ardent supporter of radiation therapy for cancer.
But these shortages aren’t just bad for current patients, experts say; their effects on cancer research may be felt for years to come. The National Cancer Institute, the federal government’s ...
Non-small cell lung cancer, oesophageal cancer, uterine cervical cancer, head and neck cancer and urothelial cancer: Nephrotoxicity, myelosuppression and nausea and vomiting (30-90%). Oxaliplatin: IV: Reacts with DNA, inducing apoptosis, non-cell cycle specific. Colorectal cancer, oesophageal cancer and gastric cancer
Murthy also urged a reassessment of the guideline limits for alcohol consumption to account for cancer risk. In the U.S., there are about 100,000 alcohol-related cancer cases and about 20,000 ...
In males aged 55 years old and over finasteride decreases the risk of low-grade prostate cancer but may increase the risk of high-grade prostate cancer and has no effect on overall survival. [32] A 2010 review found a 25% reduction in the risk of prostate cancer with 5α-reductase inhibitor. [33]